Analysts expect Anavex Life Sciences Corp (NASDAQ:AVXL) to report earnings of ($0.12) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Anavex Life Sciences’ earnings, with estimates ranging from ($0.14) to ($0.09). Anavex Life Sciences posted earnings per share of ($0.11) during the same quarter last year, which indicates a negative year over year growth rate of 9.1%. The company is expected to announce its next earnings report on Thursday, May 9th.
On average, analysts expect that Anavex Life Sciences will report full year earnings of ($0.49) per share for the current year, with EPS estimates ranging from ($0.58) to ($0.39). For the next financial year, analysts expect that the firm will report earnings of ($0.36) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Anavex Life Sciences.
Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Thursday, February 7th. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03).
Several research firms recently issued reports on AVXL. Zacks Investment Research raised shares of Anavex Life Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Roth Capital set a $10.00 price target on shares of Anavex Life Sciences and gave the stock a “buy” rating in a research note on Friday, February 8th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $7.40.
A number of institutional investors have recently added to or reduced their stakes in AVXL. Hikari Power Ltd purchased a new stake in Anavex Life Sciences during the 4th quarter worth $231,000. Park West Asset Management LLC increased its stake in Anavex Life Sciences by 1.6% during the 4th quarter. Park West Asset Management LLC now owns 3,495,615 shares of the biotechnology company’s stock worth $5,453,000 after buying an additional 53,450 shares during the period. Geode Capital Management LLC increased its stake in Anavex Life Sciences by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 291,948 shares of the biotechnology company’s stock worth $455,000 after buying an additional 3,687 shares during the period. Deutsche Bank AG purchased a new stake in Anavex Life Sciences during the 4th quarter worth $28,000. Finally, Tibra Equities Europe Ltd purchased a new stake in Anavex Life Sciences during the 1st quarter worth $258,000. 14.12% of the stock is currently owned by hedge funds and other institutional investors.
Anavex Life Sciences stock traded down $0.06 during midday trading on Wednesday, hitting $2.88. 254,011 shares of the stock were exchanged, compared to its average volume of 307,281. Anavex Life Sciences has a 1 year low of $1.25 and a 1 year high of $4.35. The company has a market capitalization of $140.07 million, a price-to-earnings ratio of -7.38 and a beta of 2.55.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.